Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Biomay AG - Product Pipeline Review - 2012

Biomay AG - Product Pipeline Review - 2012 - new company profile report published


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2012-12-14 03:50:13 - Biomay AG - Product Pipeline Review - 2012 - a new company profile report on companiesandmarkets.com

Biomay AG - Product Pipeline Review - 2012 - This pharmaceuticals report, "Biomay AG - Product Pipeline Review - 2012" provides data on the Biomay AG´s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from our proprietary databases, Biomay AG´s corporate website, SEC filings, investor presentations and featured press releases, both from Biomay AG and industry-specific third party sources, put together by This team.

Scope

- Biomay AG - Brief Biomay AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Biomay AG human therapeutic division.
- Overview of

 

 

pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Biomay AG with complete description of the product´s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Biomay AG´s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Biomay AG´s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Biomay AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Biomay AG´s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Biomay AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Biomay AG and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Biomay AG; Biomay AG - Key Therapeutics; Biomay AG - Pipeline Overview and Promising Molecules; Biomay AG - News; Biomay AG - Latest Updates; Biomay AG - Pipeline; Biomay AG - Discontinued/Dormant Projects

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Company Profile Reports www.companiesandmarkets.com/Market/All/Company-Profile?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com